Business
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
Five XIFAXAN® (rifaximin) and TRULANCE® (plecanatide) Research Posters Also to Be Prese...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023Five XIFAXAN® (rifaximin) and TRULANCE® (plecanatide) Research Posters Also to Be PresentedLAVAL, QC / ACCESSWIRE / May 8, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, (\"Salix\"), the gastroenterology (GI) business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (\"Bausch Health\") and one of the largest specialty pharmaceutical companies in the world committed to the management and treatment of gastrointestinal diseases, today will deliver a podium presentation of its research titled \"Impact of Rifaximin Use During The 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy Hospitalization on Healthcare Utilization And Costs\" during Digestive Disease Week® (DDW) 2023, which will be held virtually and in-person in Chicago, IL through Tuesday, May 9, 2023.The study led by Arun Jesudian, MD, Director of Inpatient Liver Services at NYPH/Weill Cornell, describes and compares healthcare resource utilization, including the rate of overt hepatic encephalopathy (OHE) hospitalizations, and costs during the 30-day period following an OHE hospitalization among patients who are treated with Xifaxan versus those who are not. Results showed that initiation of Xifaxan after an OHE hospitalization resulted in reduced OHE-related hospitalizations in the 30-day period following an OHE hospitalization. Further, initiation of Xifaxan immediately upon discharge after the OHE hospitalization showed a high quality of care, with a lower rate of OHE-related hospitalizations. Additionally, reduced medical costs associated with fewer hospitalizations offset the increased pharmacy costs of Xifaxan.\"The research was designed to help establish optimal clinical practices and patient health outcomes post an OHE-related hospitalization,\" said Dr. Jesudian. \"Adding to a growing body of evidence, the study supports the use of Xifaxan to both reduce re-hospitalizations and their associated medical costs after an initial OHE-related hospitalization.\"In addition, on Sunday, May 7, lead author Robert Wong, MD, MS Clinical Associate Professor (Affiliated) of Medicine in the division of Gastroenterology and Hepatology at the Stanford University School of Medicine and Staff Physici...